Why start with dogs?

The original Project Rosie essay began with a question about access: if a personalized approach requires an owner to assemble a research team, navigate unfamiliar science and coordinate multiple laboratories, how could it become available through ordinary clinical workflows?

That question remains central to N1 Therapeutics. The company is building toward a more accessible path to personalized cancer immunotherapy, starting with dogs. The current product, Neoantigen Retriever, addresses candidate discovery and prioritization inside that path.

A veterinary oncologist understands the patient’s disease, available options and suitability for a proposed study. That perspective should shape the sampling and validation programme from the beginning.

Our collaboration model asks clinics to help define the clinical question, identify suitable cases, contribute samples and connect observations with molecular evidence. It does not ask a clinician to become a bioinformatics engineer or manufacture a vaccine.

The dog and owner are at the centre of the story. The programme has to respect clinical judgment and welfare at every stage, including when the evidence does not support progressing.

Dogs develop cancers in a natural clinical setting, with biological diversity and the complexities of living patients. Comparative oncology studies can help investigate cancer biology and inform questions relevant to human research.

That connection is a reason to study carefully. A positive result in a canine study would not by itself establish a human treatment effect or authorize a human trial. Species, immune genetics, disease context and study design all matter.

The scientific target-selection problem and the delivery problem are connected. A promising candidate cannot help a patient without samples, experimental evidence, product quality and coordinated clinical follow-up.

Our founder’s operating experience is relevant here: assembling complementary talent, designing repeatable workflows and removing capital and partnership blockers. The scientific team brings computational genomics and cancer-research expertise. Specialist collaborators bring capabilities that should not be recreated casually inside a small company.

The immediate objective is a defined development programme: benchmark the computational approach, test candidates experimentally and then assess whether evidence supports a clinical proposal.

Veterinary drug studies and clinical use have their own authorization and oversight requirements. They are part of the pathway, not a shortcut around validation. A sample collaboration, positive assay result and administered dose should be recorded as different events.

The earlier essay mixed the long-term vision with projections about performance and cost. This adaptation keeps the ambition while leaving unmeasured outcomes as development questions.

Programming biology is the company’s broader ambition. Understanding life from first principles is the mission behind it. Personalized cancer vaccines are the first application we are pursuing.

We want the complete pathway to become easier to access, faster to coordinate and more affordable to deliver. The way to get there is to build the evidence and the operating model together, one clearly defined stage at a time.